A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy of Xeloda in the treatment of brain metastases
in breast cancer patients with central nervous system (CNS) progression after whole brain
radiotherapy. Patients will receive xeloda 1000mg/m2 po bid on days 1-14 of each 3 week
cycle. The anticipated time on study treatment is until disease progression, and the target
sample size is <100 individuals.